entertainment -WSS

entertainment

author：focus 2025-10-03 00:22:17 - browse：7324

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Mass General, Mayo Clinic look to monetize custom

entertainment

WSS

NEJM study measures Covid brain fog, impact on IQ

HPV vaccine, cervical cancer study delivers historic results

There's an unseen cost to disruptive road

Redefining sustainability for the pharmaceutical industry

Medicare isn't yet testing food as medicine

Change Healthcare cyberattack shows risk of industry consolidation

focus

entertainment

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

High breast density mammograms need follow

Novavax promises a turnaround & Lilly roils the obesity market

Dog Aging Project founders on what lies ahead after losing funding

How to save PrEP access — and even expand it

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

New air purifier tech could be key to improving indoor air quality

5 ways to address the shortage of health care workers

What does generative AI mean for health care? We asked experts

Printout prescription drug information shouldn’t go digital

focus

Dog Aging Project founders on what lies ahead after losing funding

Redefining sustainability for the pharmaceutical industry

FDA sets aggressive timeline for overhauling inspection procedures

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Are embryos people? Reproductive medicine's future depends on the answer

STAT Madness 2024: Meet the contenders

entertainment

hotspot

entertainment

hotspot